TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2010

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

Suresh S Ramalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.